Strides Shasun gets USFDA nod for kidney stone tablets

Updated: Tue, Sep 12, 2017
10:39 am
PTI
RELATED NEWS
Expert Views: BIG! India's retail inflation eases to 4.59% in December Expert Views: BIG! India's retail inflation eases to 4.59% in December
Budget 2021 Expectations – HOME BUYERS to benefit if Govt accepts this demand; JLL CEO lists following demands Budget 2021 Expectations – HOME BUYERS to benefit if Govt accepts this demand; JLL CEO lists following demands
Jobs, land prices, Covid-19 vaccine, rural India, household savings, NBFCs, banks, consumption, capex - Positives and Negatives | EXPLAINED Jobs, land prices, Covid-19 vaccine, rural India, household savings, NBFCs, banks, consumption, capex - Positives and Negatives | EXPLAINED

Strides Shasun today said it has received approval from the US health regulator for potassium citrate extended release tablets used to prevent certain types of kidney stones.

In a BSE filing, Strides Shasun said it has received approval from the United States Food and Drug Administration (US FDA) for potassium citrate extended release tablets USP 5 mEq, 10 mEq and 15 mEq.

Strides Shasun said it will be the second generic player to commercialise the product and will launch it immediately.

Citing IMS sales data, the company said the US market for the approved product is approximately USD 110 million.

The company's stock was trading 2.79 per cent higher at Rs 967.55 per scrip on BSE.

 

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.